Cargando…

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells

PURPOSE OF THE STUDY: Reduced levels of the tumor suppressor protein CCDC6 sensitize cancer cells to the treatment with PARP-inhibitors. The turnover of CCDC6 protein is regulated by the de-ubiquitinase USP7, which also controls the androgen receptor (AR) stability. Here, we correlated the expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morra, Francesco, Merolla, Francesco, Napolitano, Virginia, Ilardi, Gennaro, Miro, Caterina, Paladino, Simona, Staibano, Stefania, Cerrato, Aniello, Celetti, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458250/ https://www.ncbi.nlm.nih.gov/pubmed/28415632 http://dx.doi.org/10.18632/oncotarget.16463

Ejemplares similares

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer
por: Morra, Francesco, et al.
Publicado: (2019)

CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC
por: Morra, Francesco, et al.
Publicado: (2019)

FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC
por: Morra, Francesco, et al.
Publicado: (2015)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
por: Cerrato, Aniello, et al.
Publicado: (2016)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
por: Criscuolo, Daniela, et al.
Publicado: (2019)

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019)

NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells
por: Cerrato, Aniello, et al.
Publicado: (2019)

Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress
por: Napolitano, Virginia, et al.
Publicado: (2021)

Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors
por: Staibano, Stefania, et al.
Publicado: (2013)

Retraction Note: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors
por: Staibano, Stefania, et al.
Publicado: (2021)

FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC?
por: Russo, Daniela, et al.
Publicado: (2017)

Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer
por: Mascolo, Massimo, et al.
Publicado: (2012)

Epigenetic Disregulation in Oral Cancer
por: Mascolo, Massimo, et al.
Publicado: (2012)

Tissue Microarray-Based Evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as Tumour Prognostic Marker
por: Mascolo, Massimo, et al.
Publicado: (2012)

HPV Virus Transcriptional Status Assessment in a Case of Sinonasal Carcinoma
por: Ilardi, Gennaro, et al.
Publicado: (2018)

Identification of Sumoylation Sites in CCDC6, the First Identified RET Partner Gene in Papillary Thyroid Carcinoma, Uncovers a Mode of Regulating CCDC6 Function on CREB1 Transcriptional Activity
por: Luise, Chiara, et al.
Publicado: (2012)

Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma
por: Russo, Daniela, et al.
Publicado: (2021)

The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis
por: Morra, Francesco, et al.
Publicado: (2021)

A rare case of coexistence of metastasis from head and neck squamous cell carcinoma and tuberculosis within a neck lymph node
por: Caroppo, Danila, et al.
Publicado: (2015)

Epigenetics of oral and oropharyngeal cancers (Review)
por: Russo, Daniela, et al.
Publicado: (2020)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

Expression of P16INK4a in Uveal Melanoma: New Perspectives
por: Russo, Daniela, et al.
Publicado: (2020)

MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors
por: Rossi, Matteo, et al.
Publicado: (2016)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
por: Peng, Yihan, et al.
Publicado: (2019)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

A Machine-learning Approach for the Assessment of the Proliferative Compartment of Solid Tumors on Hematoxylin-Eosin-Stained Sections
por: Martino, Francesco, et al.
Publicado: (2020)

Histopathological Image Deep Feature Representation for CBIR in Smart PACS
por: Tommasino, Cristian, et al.
Publicado: (2023)

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
por: Criscuolo, Daniela, et al.
Publicado: (2022)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ll36dj8l4kdejmj734clhkmhl